Replimune Group (REPL)CEO sold ~$202K

~$202K

Approx. value · 25K sh @ $8.06

344K

Holds after · shares reported

Traded

May 20, 2025

Filed

May 23, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 20, 2025 · this disclosureInsiderCEO sold ~$202K of REPL shares in the open market

What came next

1. May 20, 2025Insider · 5 peopleInsiders: 5 sales (~$401K)
2. Aug 15, 2025InsiderCFO sold ~$49K of REPL shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Replimune Group

For Replimune Group, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REPL page.

Other recent filings by Sushil Patel, Chief Executive Officer

• SEC Form 4 at Replimune Group (REPL)Dec 19, 2024
• SEC Form 4 at Revolution Medicines (RVMD)Nov 4, 2024

The full history of Sushil Patel, Chief Executive Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Replimune Group

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRNov 14, 2025
• SEC Form 4Aug 20, 2025

Everything OQRO holds on this company is on its REPL page.